Sana Biotechnology Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good afternoon. I'm Salveen Richter Biotechnology Analyst at Goldman Sachs. Thanks for joining us. We're really pleased to have the Sana team here with us, of which we have Steve Harr, President and CEO Nate Hardy, CFO; and Nicky Keith, VP of Finance.
With that, I'm going to turn it over to Steve to make a couple of opening comments.
Thank you, Salveen. And thank you for hosting us, and thank you to everybody who's listening for joining.
And before we begin, I presume everybody knows, we'll be making forward-looking statements, and we spend a whole bunch of time on our risk factors internally. So please do peruse at your leisure.
So Sana was founded under the belief that one of, if not the most important transformation that will occur in medicine over the next 10 to 20 years, is the ability to modulate genes in use cells as medicine. So we call engineered cells. And our goal is nothing
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
